Kārtējā vakcīna pret HIV. Nesteidzieties priecāties!
Apskatīt komentārus (0)
05.10.2011
Spāņu zinātnieki notestējuši vakcīnu MVA-B un konstatējuši, ka tā 92% gadījumu iniciējusi imūno atbildi uz HIV, raksta The Telegraph. Profesors Marjano Estebans, minētā projekta vadītājs Nacionālajā biotehniskas centrā Madridē, konstatē: pateicoties vakcīnai, organisms sāk atpazīt HIV.
Zināms, ka vakcīna satur četrus vīrusa gēnus, kas stimulē T un B limfocītus balto asins šūnu tipus. Dažādie limfocīti ir ieprogrammēti cīnīties ar dažādiem patogēnu veidiem. HIV viņi nespēj viegli uzvarēt, tāpēc limfocītiem nepieciešams treniņš. B-šūnas izstrādā antivielas, kas vīrusiem uzbrūk tad, kad tie vēl nav paguvuši inficēt šūnas, savukārt T-šūnas atklāj un iznīcina inficētās šūnas.
Piedāvātā vakcīna divām trešdaļām brīvprātīgo 11 mēnešus pēc vakcinācijas ļāva izstrādāt uz HIV orientētas antivielas. Vairāk nekā 30% izstrādājās T-šūnu tips ar nosaukumu CD4+, kas cīnās ar HIV, bet pārējiem vēl viens šūnu tips CD8+. Kaut imūnā atbilde tika izsaukta, tas vēl nenozīmē, ka vakcīna pasargā no vīrusa. Tās efektivitāti zinātnieki grasās pārbaudīt uz cilvēkiem ar HIV. Iespējams, šai vakcīnai izdosies samazināt vīrusa koncentrāciju asinīs.
Vairāk materiālu krievu valodā lasiet http://www.apvienibahiv.lv/index.php?p=9627&lang=951&a=2&b=1&lbu=18146
Atsauksme angļu valodā:
U.S. Doctor Cautious About HIV Vaccine | Published September 29, 2011 | NewsCore
A New York City-based infectious disease specialist said a new vaccine developed by Spanish scientists, which could turn HIV into minor infection status, is reason to be cautiously optimistic.
Dr. Joseph Rahimian said Thursday news of an HIV vaccine is certainly exciting, but questions remain.
An HIV vaccine has been the holy grail for infectious disease doctors for a very long time, Rahimian said. There are a lot of people interested in creating one and obviously a lot of demand for it, so there would be a lot of excitement if this research is accurate.
The vaccine, developed by scientists at the Spanish Superior Scientific Research Council (CSIC) in Madrid, works by training the immune system to detect HIV and learn how to combat the virus.
In a trial involving 30 healthy volunteers, scientists found that 90 percent of those who were given the MVA-B vaccine developed an immunity against the virus and 85 percent maintained this for a year.
Professor Mariano Esteban, from CSIC, said, "MVA-B vaccine has proven to be as powerful as any other vaccine currently being studied, or even more."
He said the vaccine was like showing the body a picture of the HIV, "so that it is able to recognize it if it sees it again in the future."
"If the virus enters the body and tries to develop in a cell, the immune system is ready to inactivate the virus and destroy the infected cell," he added. Scientists hope that if bigger trials are successful, HIV would no longer cause AIDS and would be much less contagious.
'"If this genetic cocktail passes Phase II and Phase III future clinic trials, and makes it into production, in the future HIV could be compared to herpes virus nowadays," according to the study.
However, Rahimian said this study needs much more room to grow.
The population that they used is very small, and they followed them out to one year. So one important question is how long does this last for? A vaccine that has to be given repeatedly every year is less exciting than a vaccine that can give long-term immunity, he said.
On the other hand, Rahimian pointed out there are some vaccines given every year, which are successful, like the flu shot.
I would say many people have tried to create vaccines, and it is a very difficult task, so any enthusiasm for a successful vaccine is guarded, he said.
Newscore contributed to this report. Read more: http://www.foxnews.com/health/2011/09/29/new-vaccine-could-turn-hiv-into-minor-infection/#ixzz1ZRG71epk
Atpakaļ